[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dry-eye-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dry-eye-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,44,71,94,112,136,158,180,200,223,244,268,289,311,334,356,376,402,427,447,472],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100634530","evaluation-of-tears-naturale-free-and-tears-naturale-ii-lubricant-eye-drops-100634530",false,"NCT07540884","Evaluation of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops","Evaluation of the Safety and Effectiveness of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops in Subjects With Dry Eye Disease","Key Inclusion Criteria:\n\n* Able to read, understand, and sign an Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC) approved informed consent form in English or French.\n* Able to attend all study visits as required as per protocol.\n* Mild to moderate dry eye disease.\n* Willing to discontinue use of all habitual artificial tear supplements and use only the study device for the entire study duration.\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Any known allergic reactions to the study products or its ingredients.\n* Ocular injury to either eye in the past 3 months prior to screening.\n* Ocular surgery within the previous 6 months or ocular surgery planned during the study.\n* Use of any systemic medication known to cause dry eye for less than 1 month before the Screening\u002FBaseline visit.\n* Other protocol-defined exclusion criteria may apply.","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this post-market clinical follow-up (PMCF) study is to describe the effectiveness and safety of Tears Naturale® Free and Tears Naturale® II lubricant eye drops in subjects experiencing dry eye (DE) symptoms.",[26],"Dry Eye Disease",[28,29,30],"lubricating eye drops","dry eyes","artificial tears","RECRUITING","2026-06-12",{"date":34,"type":35},"2026-06-15","ACTUAL",{"date":37,"type":35},"2026-06-04",{"date":39,"type":20},"2026-08",{"name":41,"class":42},"Alcon Research","INDUSTRY",6,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100585534","phase-3-phase-iii-study-of-topical-fibrinogen-depleted-human-platelet-lysate-compared-to-placebo-for-moderate-to-severe-dry-eye-100585534","NCT06903611","Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye","CAMOMILE-2: Phase III Randomized, Double-Masked, Safety and Efficacy Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Vehicle Control for the Treatment of Moderate to Severe Dry Eye","CAMOMILE-2","Inclusion Criteria:\n\n1. Male or female subjects who at the time of consent are 18 years of age or older, if participating at a study site located in the U.S.\n2. Having a self-reported history of dry eye disease within the past 6 months.\n3. NEI Corneal Fluorescein Staining Score in at least one eye at screening and at Day 0 (pre-randomization) that is ≥ 6 (total score)as determined by the investigator.\n4. Visual Analog Scale (VAS) Symptom Index-Eye Dryness\u002FEye Discomfort total score (pre-dose) that is ≥ 40 points at screening and at Day 0 (pre-randomization).\n5. Willingness to have both the right and left eyes treated in the study.\n6. Willingness to discontinue contact lenses and all current DED treatments except artificial tears.\n7. Be able to demonstrate ability to use study medication bottle; this can be documented on study bottle used during washout period.\n8. Female subjects must be either: (1) of non-childbearing potential; or, (2) of childbearing potential and using an acceptable method of birth control with a negative pregnancy test :\n\n   1. Females of Non-childbearing Potential: Surgically sterilized (e.g., hysterectomy or bilateral oophorectomy) prior to screening; or, post-menopausal (i.e., no menstrual bleeding for at least 1 year prior to screening; or with a negative pregnancy test if less than 1 year post-menopausal).\n   2. Females of Childbearing Potential: Must agree to use a highly effective acceptable form of birth control (e.g., established hormonal birth control, or double barrier method: intrauterine device plus condom or spermicidal gel plus condom) from 21 days prior to dosing until 7 days after dosing.\n9. Providing written Informed Consent consistent with privacy language as per national regulations (e.g., HIPAA authorization) with signature obtained from the subject or legally authorized representative prior to the performance of any study related procedures (including withdrawal of prohibited medication.\n10. Willingness and ability to comply with schedule for follow-up visits and postoperative evaluations.\n\n    \\-\n\nExclusion Criteria:\n\n* Subjects who meet any of the following exclusion criteria for one or both eyes at screening will not be enrolled in the study. Subjects who meet any of the following exclusion criteria for one or both eyes on Day 0 will not be randomized and will be withdrawn from the study as screen failures:\n\n  1. Any abnormal lid anatomy or blinking function in either eye.\n  2. Using any topical ocular treatment other than the following medications:\n\n     a. Artificial Tears: Preservative-free artificial tears may be used as needed before and\u002For during the study. Whenever practicable, the same brand of artificial tears should be used throughout the study and its use documented in the patient diary throughout study participation.\n  3. Previous ocular surgery of any type (including lacrimal, corneal and trauma), except:\n\n     1. Non-refractive laser eye surgery of any type in either eye performed more than 3 months before screening is permitted.\n     2. Refractive surgery in either eye performed more than 6 months before screening is permitted.\n     3. Cataract surgery in either eye performed more than 3 months before screening is permitted\n  4. Any ocular anomaly that, in the investigator's opinion, interferes with the ocular surface, including:\n\n     1. Active ocular herpes simplex virus infection\n     2. Recurrent corneal erosion\n     3. Symptomatic epithelial basement membrane dystrophy\n     4. Mucus fishing syndrome\n     5. Giant papillary conjunctivitis\n     6. Post-radiation keratitis\n     7. Stevens-Johnson syndrome\n     8. Corneal ulcer\n     9. Abnormalities of the nasolacrimal drainage system\n     10. Chemical injury\n     11. Diagnosed significant anterior blepharitis and\u002For progressive pterygium\n  5. Current history of ocular infection (viral, bacterial, fungal), disease or inflammation (e.g., uveitis) not associated with dry eye, unless the disorder or disease is, in the investigator's opinion:\n\n     1. Stable for at least 3 months before the Screening Visit; and,\n     2. Not likely to impact or possibly interfere with the interpretation of study results.\n  6. Subjects with a current intraocular infection or with any other current eye or systemic condition (e.g., severe endothelial corneal dystrophy) that, in the investigator's opinion, would interfere with the dry eye evaluation or treatment, or for which the potential benefits of CAM-101 do not outweigh the risks.\n  7. History of ocular allergy (including seasonal conjunctivitis) or chronic conjunctivitis other than that secondary to dry eye.\n  8. Known hypersensitivity to the components of CAM-101 or the vehicle control (fibrinogen-depleted human platelet lysate; Plasma-Lyte A).\n  9. Known hypersensitivity to one of the procedural medications (e.g., proparacaine, fluorescein) unless a suitable alternative medication is available.\n  10. Inability to refrain from contact lens wear during the study, including the vehicle control run-in period.\n  11. Anticipated need for temporary or permanent punctum plugs during the study. (If punctum plugs have been in place for at least 4 weeks prior to the screening visit, the plugs are allowed to remain in place during the study. ) Patients must remain symptomatic for DED post punctal plug insertion.\n  12. Any ocular disease or ocular condition not stabilized within 1 month (30 days) before the screening visit.\n  13. Any clinically significant systemic disease or condition that is inadequately controlled (e.g., diabetes, thyroid disease, autoimmune disease) or not stabilized within 4 weeks before the screening visit.\n  14. Inability or unwillingness to discontinue use of autologous serum eye drops or platelet rich plasma eye drops during the 2-week run-in period and throughout the remainder of the study.\n  15. Female subjects who are pregnant or lactating or plan to become pregnant during the course of the study.\n  16. Subjects not under legal guardianship who, in the investigator's opinion, lack the mental capacity to provide written informed consent for study participation.",true,{"count":54,"type":20},475,[56],"PHASE3","Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for one year.",[26,59,60,61],"Dry Eye","Dry Eyes Chronic","Dry Eye Syndromes","NOT_YET_RECRUITING","2026-06-11",{"date":32,"type":35},{"date":66,"type":20},"2026-10-01",{"date":68,"type":20},"2028-12",{"name":70,"class":42},"Cambium Bio Limited",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100505751","efficacy-and-safety-of-bufy02-versus-trb02-in-the-treatment-of-dry-eye-disease-100505751","NCT05865457","Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease","Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease: a Non-inferiority Investigation","BUSTON-02","Inclusion Criteria include:\n\n* At least a 3-month documented history of bilateral dry eye syndrome needing artificial tears;\n* At least one eye with Oxford score ≥ 4 and ≤ 9;\n* At least one objective sign of tear deficiency (in at least one eligible eye);\n* Having a health insurance.\n\nExclusion Criteria include:\n\n* Wear of contact lenses starting within the last 2 months;\n* Best-corrected visual acuity (BCVA) \\> 1.00;\n* Severe DED with one of the listed conditions:\n* Severe blepharitis;\n* Seasonal allergy;\n* Any issues of the ocular surface not related to DED;\n* History of ocular trauma, infection or inflammation not related to DED;\n* History of ocular surgery, including laser surgery;\n* Unstable glaucoma;\n* Use of artificial tears with preservative within the last 2 weeks;\n* Systemic (enteral or parenteral) or local (topical) use of one of the listed medications:\n* Known hypersensitivity to any constituent of the study treatments;\n* Pregnancy or breastfeeding;\n* Participation in another clinical study within the last 90 days;\n* Legally restricted autonomy, freedom of decision and action.",{"count":80,"type":20},80,[23],"The goal of this interventional investigation is to compare BUFY02 with TRB02 in the treatment of patients with dry eye disease. The main questions it aims to answer are:\n\n* Is BUFY02 non-inferior to TRB02 in terms of signs of DED?\n* Is BUFY02 non-inferior to TRB02 in terms of symptoms of DED?\n\nParticipants will be asked to:\n\n* Visit the trial site at 4 different timepoints\n* Use the allocated study treatment everyday until the end of the study (during 3 months)\n* Be examined by the investigator\n* Complete several questionnaires\n* Return unused study treatment.\n\nResearchers will compare BUFY02 to TRB02 to see if both study treatments provide similar effects on signs and symptoms of the disease, together with comparable safety.",[26],"2026-06-01",{"date":86,"type":35},"2026-06-03",{"date":88,"type":35},"2025-09-25",{"date":90,"type":20},"2027-06",{"name":92,"class":42},"TRB Chemedica International SA",5,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":110,"locationsCount":111},"100505745","efficacy-and-safety-of-bufy01-versus-svs20-in-the-treatment-of-dry-eye-disease-100505745","NCT05865379","Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease","Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease: a Non-inferiority Investigation","BUSTON-01","Inclusion Criteria includes:\n\n* At least a 3-month documented history of bilateral dry eye syndrome needing artificial tears;\n* At least one eye with Oxford score ≥ 4 and ≤ 9;\n* At least one objective sign of tear deficiency (in at least one eligible eye);\n* Having a health insurance.\n\nExclusion Criteria includes:\n\n* Wear of contact lenses starting within the last 2 months;\n* Best-corrected visual acuity (BCVA) \\> 1.00;\n* Severe DED with one of the listed conditions:\n* Severe blepharitis;\n* Seasonal allergy;\n* Any issues of the ocular surface not related to DED;\n* History of ocular trauma, infection or inflammation not related to DED;\n* History of ocular surgery, including laser surgery;\n* Unstable glaucoma;\n* Use of artificial tears with preservative within the last 2 weeks;\n* Systemic (enteral or parenteral) or local (topical) use of one of the listed medications:\n* Known hypersensitivity to any constituent of the study treatments;\n* Pregnancy or breastfeeding;\n* Participation in another clinical study within the last 90 days;\n* Legally restricted autonomy, freedom of decision and action.",{"count":80,"type":20},[23],"The goal of this interventional investigation is to compare BUFY01 with SVS20 in the treatment of patients with dry eye disease. The main questions it aims to answer are:\n\n* Is BUFY01 non-inferior to SVS20 in terms of signs of DED?\n* Is BUFY01 non-inferior to SVS20 in terms of symptoms of DED?\n\nParticipants will be asked to:\n\n* Visit the trial site at 4 different timepoints\n* Use the allocated study treatment everyday until the end of the study (during 3 months)\n* Be examined by the investigator\n* Complete several questionnaires\n* Return unused study treatment.\n\nResearchers will compare BUFY01 to SVS20 to see if both study treatments provide similar effects on signs and symptoms of the disease, together with comparable safety.",[26],{"date":86,"type":35},{"date":108,"type":20},"2026-06",{"date":90,"type":20},{"name":92,"class":42},2,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":135},"100640271","early-phase-1-human-umbilical-cord-mesenchymal-stem-cell-derived-small-extracellular-vesicles-for-the-treatment-of-dry-eye-disease-100640271","NCT07623382","Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease","Clinical Study on the Treatment of Dry Eye With Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles Eye Drops","Inclusion Criteria:\n\n* Subjects who voluntarily participate and sign the informed consent form, are willing to comply with the treatment schedule specified in the study protocol, and attend follow-up visits on time.\n* Aged ≥ 18 years, with no gender restriction.\n* Best-corrected visual acuity (BCVA) of both eyes (OU) ≥ 0.1 at the Screening Visit (Visit 1, V1).\n* History of dry eye disease in both eyes prior to the Screening Visit (Visit 1, V1), with at least one of the following subjective symptoms: ocular dryness, foreign body sensation, burning sensation, eye fatigue, discomfort, redness, or fluctuating visual acuity.\n* Meeting one of the following criteria at the Screening Visit (Visit 1, V1):\n\n  i. Positive corneal fluorescein staining, TBUT \\\u003C 10 s, and OSDI score ≥ 13; ii. Negative corneal fluorescein staining, TBUT \\\u003C 5 s, and OSDI score ≥ 13\n\nExclusion Criteria:\n\n* Subjects with current ocular herpes or any other ocular infection or inflammation, or a history of ocular herpes or any other ocular infection within 30 days prior to screening.\n* Subjects with ocular diseases including structural abnormalities of the eyelid margin (ectropion, entropion, eyelid laxity, etc.), severe conjunctivochalasis, Salzmann nodular corneal degeneration, damaged conjunctival goblet cells (e.g., vitamin A deficiency), progressive pterygium, wet age-related macular degeneration (wAMD), glaucoma, diabetic retinopathy, retinal vein occlusion, etc., which, in the investigator's opinion, may increase subject risk or interfere with study outcomes.\n* Subjects with secondary ocular scarring that, in the investigator's assessment, may affect subject compliance or outcome evaluation (e.g., radiation scars, chemical burns, Stevens-Johnson syndrome, cicatricial pemphigoid, etc.).\n* Subjects with secondary Sjögren's syndrome or other autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.), unless the subject meets all of the following conditions:\n\n  1. Not receiving steroids, immunomodulatory, or immunosuppressive agents for the disease;\n  2. The investigator determines that the medical condition will not impact study results.\n* Subjects with a history of organ or bone marrow transplantation.\n* Subjects who wore contact lenses within 30 days prior to screening.\n* Subjects who received physical therapy for dry eye within 30 days prior to screening, including eyelid scrubbing, meibomian gland expression, warm compresses, fuming, or IPL laser therapy for bilateral dry eye.\n* Subjects who received oral aspirin or aspirin-containing medications, or used NSAIDs (topical ocular or systemic), or drugs known to induce ocular dryness (e.g., anticholinergics, SSRIs, etc.) within 30 days before dosing, unless the subject has been on a stable dose of such medication for at least 30 days before the baseline visit, with no expected changes during the study.\n* Subjects who used the following medications within the specified periods before dosing:\n\n  1. Antihistamines (ocular or systemic) or any topical ophthalmic medications within 14 days before dosing;\n  2. Artificial tears within 14 days before dosing;\n  3. Steroids or mast cell stabilizers (ocular or systemic) within 30 days before dosing;\n  4. Varenicline or diquafosol within 30 days before dosing;\n  5. Topical ocular cyclosporine or tacrolimus within 6 weeks before dosing.\n* Subjects with punctal plugs implantation or a history of punctal cautery within 12 weeks prior to screening.\n* Subjects who used antiglaucoma medications within 3 months prior to screening, had non-laser glaucoma surgery, or underwent glaucoma laser surgery within 6 months prior to the screening visit.\n* Subjects who underwent Nd:YAG laser capsulotomy within 6 months prior to screening, or corneal refractive surgery (e.g., LASIK) within 12 months prior to screening.\n* Subjects with known allergy to fluorescein, multiple drug allergies, or severe allergic diseases.\n* Subjects with other poorly controlled clinical conditions, such as severe chronic infection, severe cardiopulmonary disease, uncontrolled hypertension (defined as systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg despite antihypertensive treatment), uncontrolled diabetes mellitus, malignant tumors, etc.\n* Female subjects with a positive pregnancy test or lactating subjects; female subjects of childbearing potential or male subjects whose partners are of childbearing potential who are unwilling to use contraception during the study and for 1 month after the last dose of study medication.\n* Subjects who participated in any other clinical trial of investigational drugs or devices within 30 days prior to screening.\n* Any other conditions deemed by the investigator to make the subject ineligible for enrollment (e.g., depression, etc.).",{"count":120,"type":20},20,[122],"EARLY_PHASE1","This clinical trial aims to preliminarily evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell small extracellular vesicle eye drops in patients with dry eye disease.\n\n1. Human mesenchymal stem cell small extracellular vesicle eye drops:\n\n   Administer one drop each time, 4 times daily, for a treatment duration of 4 weeks.\n2. During treatment, subjects will be followed up and undergo examinations and related tests weekly.\n3. After completion of treatment, follow-up visits will be conducted every 2 weeks for a total of 2 visits.\n4. Subsequently, subjects will enter a long-term follow-up period, with follow-up assessments at 3 months and 6 months to observe longer-term safety and efficacy.\n5. Subjects shall record medication usage and any possible adverse reactions.",[26,125],"Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles","2026-05-28",{"date":86,"type":35},{"date":129,"type":35},"2026-03-31",{"date":131,"type":20},"2026-11-30",{"name":133,"class":134},"The First Affiliated Hospital of Xiamen University","OTHER",1,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":141,"conditions":147,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100602831","phase-2-a-study-evaluating-the-safety-and-efficacy-of-a-fixed-dose-combination-for-dry-eye-disease-100602831","NCT07128628","A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease","A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast\u002FPerfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease","Inclusion Criteria:\n\nThis study will include subjects who meet all of the following inclusion criteria:\n\n* Voluntarily provide written informed consent\n* ≥18 years of age\n* Subject-reported history of DED OU for at least 6 months\n* Same eye satisfies the criteria for dry eye signs at both screening and baseline\u002Frandomization\n* The criteria for dry eye symptoms are met at both screening and baseline\u002Frandomization\n* As needed (PRN) or scheduled use of non-prescription (OTC) artificial tear, gels, or lubricants for symptoms of dry eye within the past 30 days\n* Able and willing to follow instructions, including participation in all trial assessments and visits\n\nExclusion Criteria:\n\nThis study will exclude subjects who meet any of the following exclusion criteria (Note: Ocular exclusion criteria are relevant to both eyes, such that meeting a criterion in either eye excludes the subject from the study):\n\n* Known allergy or sensitivity to any study treatment (or any of its components)\n* Best-corrected visual acuity (BCVA) of 0.7 logarithm of the minimum angle of resolution (logMAR) or worse (50 Early Treatment Diabetic Retinopathy Study \\[ETDRS\\] letters; Snellen equivalent score of 20\u002F100 or worse) at Visit 1 (Screening) or Visit 2 (baseline\u002Frandomization)\n* Any clinically significant (CS) ocular surface slit-lamp findings at Visit 1 (Screening) or Visit 2 (baseline\u002Frandomization), or findings that may interfere with trial parameters in the opinion of the Investigator.\n* Use of any of any ocular therapies within 30 days.\n* Unable or unwilling to stop current topical dry eye treatments\n\nAdditional criteria per protocol",{"count":144,"type":20},423,[146],"PHASE2",[26],"2026-03-11",{"date":150,"type":35},"2026-03-13",{"date":152,"type":35},"2025-10-24",{"date":154,"type":20},"2026-11",{"name":156,"class":42},"Bausch & Lomb Incorporated",32,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":166,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":178,"locationsCount":179},"100611293","an-evaluation-of-the-safety-and-tolerability-of-ocular-lubricants-100611293","NCT07238699","An Evaluation of the Safety and Tolerability of Ocular Lubricants","Inclusion Criteria:\n\n* Subject must be willing and able to understand and sign an ethics committee approved informed consent form.\n* Subject must be willing and able to attend all study visits as required by the protocol.\n* Subject must exhibit symptoms of dry eye at the Screening Visit.\n* Subject must currently use artificial tears.\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Has any known active ocular disease and\u002For infection.\n* Has any known infection or inflammation that requires treatment or has a systemic condition that, in the opinion of the investigator, may affect a study outcome variable.\n* Any ocular injury to either eye in the 12 weeks prior to screening.\n* Current wearer of contact lenses or has a history of contact lens wear within the previous 1 month.\n* Other protocol-defined exclusion criteria may apply.",{"count":165,"type":20},148,[23],"The purpose of this study is to evaluate the safety and tolerability of two new artificial tear formulations in subjects with moderate dry eye disease.",[26],[170,171,172],"Itchy eyes","Stinging eyes","Scratchy eyes","2026-03-09",{"date":148,"type":35},{"date":176,"type":35},"2026-03-04",{"date":39,"type":20},{"name":41,"class":42},4,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":135},"100628083","a-study-to-evaluate-the-safety-and-effectiveness-of-perfluorohexyloctane-eye-drops-on-treatment-of-dry-eye-disease-ded-related-to-meibomian-gland-dysfunction-mgd-100628083","NCT07457021","A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD)","Treating Dry Eye Disease Related to Meibomian Gland Dysfunction With Perfluorohexyloctane Eye Drops : A Prospective, Multicenter, Real-world Study","Inclusion Criteria:\n\n1. Patients who meet the diagnostic criteria for meibomian gland dysfunction (MGD) as stipulated in the \"Expert Consensus on Diagnosis and Treatment of Meibomian Gland Dysfunction in China (2023)\"\n2. Patients who meet the diagnostic criteria for dry eye as stipulated in the \"Clinical Expert Consensus on Dry Eye in China (2020)\"\n3. Be at least 18 years old.\n4. Voluntarily participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Patients who have a history of allergy to any component of the drugs or tests intended for use in the study (such as perfluorohexyloctane, fluorescein);\n2. Patients who used perfluorohexyloctane eye drops within 2 weeks before enrollment;\n3. Patients who have participated in or are currently participating in clinical trials of other drugs or devices within one month;\n4. Situations where researchers determine that may pose significant risks to patients, confuse the trial results, or seriously interfere with patients' participation in the trial (including language barriers).",{"count":188,"type":20},2000,"OBSERVATIONAL","Perfluorohexyloctane eye drops is the only drug in China approved for treating Dry Eye Disease (DED) related to Meibomian Gland Dysfunction (MGD), its efficacy and safety in the clinical practice of treating DED related to MGD in the real world, whether in combination with or without various other treatment methods (other drugs or physical therapy) , remain to be explored.\n\nThis study aims to collect data on the treatment of DED related to MGD with perfluorohexyloctane under real medical conditions. Through analysis, it seeks to obtain clinical evidence of the product's application value and potential benefits or risks, providing evidence for the treatment of DED elated to MGD with perfluorohexyloctane under real medical conditions.",[26],"2026-03-06",{"date":173,"type":35},{"date":195,"type":20},"2026-03-01",{"date":197,"type":20},"2029-09-30",{"name":199,"class":134},"Xiamen Ophthalmology Center Affiliated to Xiamen University",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":219,"leadSponsor":221,"locationsCount":135},"100620915","a-study-on-the-correlation-between-tear-iron-levels-and-the-severity-of-dry-eye-disease-100620915","NCT07363824","A Study on the Correlation Between Tear Iron Levels and the Severity of Dry Eye Disease.","Inclusion Criteria:\n\n* Aged between 18 and 70 years, inclusive.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* History or clinical suspicion of significant systemic conditions: hematologic diseases, severe systemic infections, malignancies (treated or untreated), or chronic hepatic\u002Frenal insufficiency.\n* Use of artificial tears or any topical eye drops within 2 hours prior to examination.\n* Active ocular allergy, infection, or severe blepharitis within the past 1 month.\n* Systemic or topical use of antibiotics, corticosteroids, NSAIDs, or immunosuppressants within the past 1 month.\n* History of contact lens wear within the past 1 month.\n* History of blood transfusion, ocular surgery, or significant ocular trauma within the past 6 months.\n* Women who are pregnant, breastfeeding, or postmenopausal women undergoing hormone replacement therapy.\n* Known hypersensitivity to fluorescein sodium.","70 Years",{"count":208,"type":20},52,"This study aims to see if the amount of iron in tears is linked to how severe dry eye disease is. We hope this can lead to a new way to help diagnose and understand dry eye. This is an observational study. We will compare tear samples from people with dry eye to samples from people with healthy eyes. We will measure the iron content in the tears and see if it correlates with standard dry eye test results and symptom scores.",[26,211],"Iron",[213,214],"DED","iron","2026-02-06",{"date":217,"type":35},"2026-02-10",{"date":215,"type":35},{"date":220,"type":20},"2029-05",{"name":222,"class":134},"Shanghai Changzheng Hospital",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":135},"100435170","2177gccciding-tx-targets-and-biomarkers-for-ocular-surface-disease-in-pt-w-ogvhd-100435170","NCT04946721","2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w\u002F oGVHD","2177GCCC: Identifying Novel Treatment Targets and Biomarkers for Ocular Surface Disease in Patients With Ocular Graft vs Host Disease (oGVHD) a Biobank Study","Inclusion Criteria:\n\n* Adult patients (≥ 18 years of age) who visit the Eye clinic either in the UMGCCC within the UMD Hospital or the UMD Faculty Physicians Ophthalmology Practice at the UMD Professional Building or satellite locations for initial visits or established visits.\n* The patient must be able to understand and sign and date the informed consent form approved by the IRB.\n\nExclusion Criteria:\n\n* Vulnerable populations: neonates, children, prisoners, institutionalized individuals.\n* Inability or refusal to provide informed consent.\n* History of ocular surgery (except refractive surgery or cataract surgery)",{"count":231,"type":20},150,"Evaluate and study the immunologic changes to the ocular surface in cancer patients.",[26,234],"oGVHD","2026-01-30",{"date":237,"type":35},"2026-02-03",{"date":239,"type":35},"2022-04-27",{"date":241,"type":20},"2027-12-31",{"name":243,"class":134},"University of Maryland, Baltimore",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":21,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":135},"100561943","vit-a-vision-clinical-investigation-100561943","NCT06596733","Vit-A-Vision® Clinical Investigation","Clinical Investigation to Evaluate the Efficacy and Safety of Vit-A-Vision® When Used in Dry Eye Disease","Inclusion Criteria:\n\n* At least 18 years old\n* Ocular Surface Disease Index (OSDI) ≧ 16\n* Median of three consecutive non-invasive tear film break-up time (NIBUT) test results less than or equal to 10 seconds in at least one eye\n* Willingness to apply the medical device under evaluation as per Instructions for Use (IfU) during the entire study duration (i.e., 33 ± 3 days)\n* Willingness to undergo a follow-up visit at day 15 ± 3 and 33 ± 3 after enrolment\n* Good understanding of written and oral speaking languages used at the centre where the study will be carried out\n\nExclusion Criteria:\n\n* Known hypersensitivity (allergy) to any of the ingredients of Vit-A-Vision: vaseline, paraffin, adeps lanae, vitamin A palmitate, dexpanthenol, α-Tocopherol acetate or cetylstearyl alcohol.\n* Severe forms of dry eye syndrome with OSDI \\> 55\n* Not willing to discontinue contact lens use during the study period\n* Refractive surgery within the last 12 months and\u002For any other ocular surgery or ocular trauma\u002Finjury within the last 4 months\n* Acute inflammatory or ocular surface disease, Sjögren's Syndrome (autoimmune disease), Stevens-Johnson Syndrome, ocular pemphigoid, and radiation-induced dry eye.\n* Use of systemic medication that could affect vision or dry eye, including essential fatty acids, unless dose has been constant for more than 3 months and is not expected to change during the study\n* Systemic concomitant medications:\n\n  * Corticosteroids within 2 months before enrolment and for the whole study period and \u002F or\n  * Tetracyclines within 1 month before selection and for the whole study period.\n  * Vitamin A supplements intake\n* Use of topical ophthalmic medication during the study or within 2 weeks prior to the first visit, other than artificial tears\n* Use of topical cyclosporine within 3 months prior to the first visit\n* Use of other eye drops\u002Fsprays (based on liposomic and\u002For oily products) during the present investigation\n* Abnormality of the nasolacrimal drainage apparatus\n* Permanent occlusion of lacrimal puncta in any eye\n* Use of temporary punctal plug in any eye within 2 months before the selection visit\n* Previous enrolment into the current investigation\n* Patients who participated in any other clinical trial within the last 30 days before selection\n* Children, pregnant and breastfeeding women\n* Participants under the influence of excessive alcohol, narcotics or benzodiazepines\n* Other diseases or characteristics judged by the investigator to be incompatible with the frequent assessments needed in this study or with reliable instillation of the products (for example: mental or physical incapacity, language comprehension, psychological disorders, dementia, geographical localisation, etc...).\n* Individuals who are deprived of liberty pursuant to an administrative order or court order or approval",{"count":252,"type":20},77,[23],"Symptoms of ocular discomfort include dryness, burning, stinging, photophobia, foreign body sensation and contact lens intolerance. These symptoms may affect basic daily activities, such as reading, driving, and working with computers. In case of moderate to severe conditions, dry eye disease is also associated with significant pain. Dry eye disease (DED) affects hundreds of millions of people throughout the world and is one of the most frequent causes of patient visits to eye care practitioners. Diagnosing, staging and determining the efficacy of therapy in DED is often challenging due to low correlation between signs and symptoms. Furthermore, its management is complicated because of its multifactorial aetiology. In general, management approaches begin with conventional, low-risk and easily accessible patient-applied therapies such as over-the-counter lubricants for early-stage disease, and progress to more advanced therapies for more severe forms of DED. In this regard, tear supplementation with ocular lubricants (artificial tears) is considered the first-line therapy and is often the only therapy used in mild to moderate disease. They are used in all stages of dry eye, either alone (in mild to moderate disease) or in combination with other treatments (in moderate to severe disease). Most tear supplements act as lubricants. Other actions may include replacement of deficient tear constituents, dilution of proinflammatory substances, reduction of tear osmolarity and protection against osmotic stress. A wide variety of artificial tear products is currently available. These products differ with respect to several variables, that include electrolyte composition, osmolarity\u002Fosmolality, viscosity, the presence or absence of preservatives and the presence or absence of compatible solutes. Although they are all considered as standard of care in treatment of dry eye disease, the effects of many of the available products have not been evaluated in clinical investigations.\n\nVit-A-Vision is an ointment for ophthalmic application that relieves symptoms such as burning, irritation, slight irritation, dryness or tiredness of the eyes.",[256,257,258,26],"Burning Eye","Irritation; Eyeball","Tired Eye","2026-01-14",{"date":261,"type":35},"2026-01-16",{"date":263,"type":35},"2025-12-19",{"date":265,"type":20},"2026-10-31",{"name":267,"class":42},"OmniVision GmbH",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":21,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":4},"100588545","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-treatment-with-csa-pg-ophthalmic-gel-in-dry-eye-patients-100588545","NCT06942793","A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients","A Phase 3, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients","Inclusion Criteria:\n\n1. Be at least 18 years of age, male or female;\n2. Provide written informed consent;\n3. Have a reported history of dry eye for at least 6 months before Visit 1;\n4. Have a clinical diagnosis of bilateral dry eye disease, including all of the following scored in at least one eye at both Visits 1 and 2;\n\n   1. Corneal fluorescein staining score in either inferior, superior, or central zone ≥ 2\n   2. Schirmer Tear Test score (STT, anesthetized) of ≤ 10 mm and ≥ 1 mm\n   3. Have an Eye Dryness Score (EDS; Visual Analogue scale, VAS) ≤80 and ≥40\n\nExclusion Criteria:\n\n1. Clinical diagnosis or history of any clinically significant ocular diseases\u002Fdisorders (e.g., age-related maculopathy that requires treatment and\u002For in the opinion of the Investigator may interfere with study parameters in Visit 1 and\u002For Visit 2;\n2. Any active ocular or systemic infection (e.g., bacterial, viral, or fungal) at Visit 1 and\u002For Visit 2;\n3. Any active ocular inflammation (e.g., iritis, uveitis, allergic conjunctivitis) at Visit 1 and\u002For Visit 2;\n4. Any conjunctival scarring history (Such as with irradiation, alkali burns, Steven Johnson syndrome, Sjogren's syndrome, cicatricial pemphigoid) or destruction of conjunctival goblet cells (e.g., neurotrophic keratitis, vitamin A deficiency) before Visit 1;\n5. Have worn contact lenses within 14 days of Visit 1 or anticipate using contact lenses during the study;\n6. Have any refractive surgery and\u002For any other ocular surgical procedure within 3 months before Visit 1; or have any ocular surgical procedure scheduled to be conducted during the study period;\n7. Have eyelid surgery within 6 months before Visit 1 or planned eyelid surgery during the study period;\n8. Have Nd:YAG (neodymium-doped yttrium aluminum garnet) laser capsulotomy within 6 months before Visit 1;\n9. Have used temporary (i.e., collagen) punctual plugs within 3 months before Visit 1 or anticipate their use during the study period;\n10. Have permanent punctual plugs inserted or have surgical punctual occlusion before Visit 1 or anticipate any such event during the study period;\n11. Use any of the following treatments in the period indicated before Visit 1 or anticipate their use at any time during the study.\n\n    Topical medications（30 days prior to Visit 1）:\n    * Restasis®, Cequa™, Tyrvaya, Eysuvis, Xiidra\n    * Topical ophthalmic non-steroidal anti-inflammatories\n    * Topical ophthalmic corticosteroids\n    * Topical ophthalmic autologous serum Exceptions: demulcent ophthalmic drops (e.g., OCCT artificial tears) may be used until Screen Visit 1, but these must be discontinued after screening.\n\n    Systemic medication (30 days before Visit 1):\n\n    Any systemic medication known to cause ocular drying (e.g., antidepressants, beta blockers) except if it was taken on a stable dosing regimen for at least 30 days before Visit 1 and is expected to be taken on the same regimen throughout the study period. The known systemic medications that can cause ocular drying include:\n    * antihistamines, antidepressants, bronchodilators, antiarrhythmics\n    * anti-Parkinson's disease drugs, antipsychotics, antitussives, anticongestants\n    * adrenoceptor blockers, thiazide diuretics, anti-leprosy drugs, antimalarials, antineoplastics anxiolytics\u002Fsleeping agents, herbs and vitamins, calcium modulators\n    * Corticosteroids (e.g., systemic steroids including intravenous, intramuscular, intraarticular, and oral steroids; facial topical steroids; dermatological steroids with high potency or large treatment areas)\n    * Cyclosporine and any other immunosuppressor\n    * Other medications that can impact dry eye disease favorably or not include various analgesics, including opiates, cannabinoids, omega-3 dietary supplements, and other agents. Such meds should be continued on study only if that represents a continuation of an unavoidable and unchanged regimen of treatment for a disease that is not otherwise excluded\n\n    Non-medicine treatment (30 days before Visit 1):\n    * LipiFlow® or other similar meibomian gland dysfunction (MGD) therapy;\n    * Eye mask with heat or steam and any other warming method of the eyelid (e.g., warm towel application);\n    * Intense pulsed light treatment;\n    * Bandage contact lenses or scleral contact lenses;\n    * Route eyelid cleaning;\n    * Any other treatment that will relieve dry eye symptoms and signs.\n12. Have a severe\u002Fserious systemic disease, chronic illness, or uncontrolled medical condition including, but not limited to, severe cardiopulmonary disease, poorly controlled hypertension, poorly controlled diabetes, and\u002For clinically significant (CS) hematologic, renal, or liver disease that in the opinion of the Investigator could interfere with study assessments or limit compliance;\n13. Be a woman who is pregnant, nursing, or planning a pregnancy;\n14. Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 5 (or early termination visit) if of childbearing potential. The non-childbearing potential is defined as a woman who is permanently sterilized (e.g., has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is post-menopausal (i.e., without menses for 12 consecutive months);\n15. Be a woman of childbearing potential who is not using an acceptable means of birth control during the study period and 30 days after the end of the study. Acceptable methods of contraception include hormonal (e.g., oral, implantable, injectable, or transdermal contraceptives), mechanical (e.g., spermicide in conjunction with a barrier such as a diaphragm or a condom), intrauterine device (IUD), or surgical sterilization of partner. For non-sexually active females, abstinence might be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use acceptable birth control as defined above for the remainder of the study;\n16. Have a known hypersensitivity or contraindication to the investigational products (IPs) or their components;\n17. Have a condition or be in a situation that the Investigator felt may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study (e.g., any planned procedure or surgery during the study period);\n18. Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days before Visit 1;\n19. In the opinion of the Investigator, be unable or unwilling to comply with the study protocol, including participation in all study assessments, visits, and dosing, or be unable to instill eye drops successfully.",{"count":276,"type":20},396,[56],"This is a phase III, multicenter, randomized, double-masked, Active-controlled design. The aims to confirm previous findings of the efficacy and safety of CsA-PG Ophthalmic Gel by comparing it to CsA Ophthalmic Gel for treating dry eye symptoms.",[26],"2025-04-24",{"date":282,"type":35},"2025-04-29",{"date":284,"type":20},"2025-05-20",{"date":286,"type":20},"2025-11-15",{"name":288,"class":42},"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":21,"phases":297,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":135},"100589528","efficacy-of-lipid-containing-artificial-tears-in-the-treatment-of-dry-eye-100589528","NCT06955585","Efficacy of Lipid-containing Artificial Tears in the Treatment of Dry Eye","Inclusion Criteria:\n\n* Ocular Surface Disease Index (OSDI) score between 14 and 50 and at least one positive diagnostic test: tear break-up time (TBUT) \\\u003C7 seconds, Schirmer I test (≤10 mm\u002F5 min), or positive corneal staining based on the Oxford grading scheme. In addition, participants must not have used artificial tears for at least two weeks prior to enrollment, even if they were previously on such therapy\n\nExclusion Criteria:\n\n* use of systemic or topical corticosteroids, active ocular infection, or ocular surgery within the last 3 months",{"count":296,"type":20},50,[23],"This clinical study involves patients with Dry Eye Disease (DED) who are visiting an ophthalmology outpatient clinic. Eligible participants must have an Ocular Surface Disease Index (OSDI) score ≥14 and \\\u003C50, and at least one positive diagnostic test: tear break-up time (TBUT) \\\u003C7 seconds, Schirmer I test \\\u003C10 mm\u002F5 min, or positive corneal staining based on the Oxford grading scale. At baseline, tear film thickness will be measured using Pentacam imaging. Participants will then receive Proluxx eye spray, applied four times daily for 28 days. After this treatment period, a follow-up examination with all baseline assessments will be repeated.",[26,59,300],"Dry Eye, Evaporative",[302,30],"dry eye",{"date":304,"type":35},"2025-05-02",{"date":306,"type":20},"2025-04-25",{"date":308,"type":20},"2025-09",{"name":310,"class":134},"University Hospital Sestre Milosrdnice",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":320,"conditions":321,"keywords":322,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":135},"100413028","ocular-microbiome-and-immune-system-in-dry-eyes-100413028","NCT04658238","Ocular Microbiome and Immune System in Dry Eyes","Associations of the Ocular Microbiome and the Immune System in Dry Eye Disease","Inclusion Criteria:\n\n* Willing to sign informed consent\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Not willing or able to sign informed consent\n* Younger than 18 years\n* Recent (3 month) history of use of systemic and\u002For topical antibiotics\n* Usage of medical eye drops (Lacrycon and other moisturizing eye drops are allowed)\n* Recent (3 month) history of ocular surgery",{"count":319,"type":20},600,"The primary objectives of this study are the characterization of the ocular microbiome as well as of the local immune system in participants with and without dry eye disease. Secondary objectives are the identification of differences in the ocular microbiome as well as in the immune system between participants with and without dry eye disease to ultimately find associations between the ocular microbiome and the immune system in dry eye disease.",[26],[323,324],"microbiome","immune system","2025-03-26",{"date":327,"type":35},"2025-04-01",{"date":329,"type":35},"2020-10-01",{"date":331,"type":20},"2026-12-31",{"name":333,"class":134},"Insel Gruppe AG, University Hospital Bern",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":21,"phases":342,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":352,"leadSponsor":354,"locationsCount":4},"100544934","phase-1-study-to-evaluating-pro-240-ophthalmic-solution-compared-to-optive-100544934","NCT06375343","Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®","Phase I Clinical Study to Evaluate the Safety and Tolerability of PRO-240 Ophthalmic Solution Compared to Optive® on the Ocular Surface of Ophthalmologically and Clinically Healthy Volunteers","Inclusion Criteria:\n\n* Having the ability to voluntarily give their signed informed consent.\n* Ophthalmologically and clinically healthy subjects.\n* Being able to and willing to comply with scheduled visits, treatment plan, and other study procedures.\n* Age ≥18 years.\n* Male or female gender.\n* Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO \\[Tubal Ligation\\]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the informed consent form \\[ICF\\]) of the use of a hormonal contraceptive method or intrauterine device (IUD) during the study period.\n* Best corrected visual acuity (BCVA) of 20\u002F30 or better in both eyes.\n* Corneal staining ≤ grade I on the Oxford Scale.\n* Having an intraocular pressure ≥ 10 and ≤ 21 mmHg.\n\nExclusion Criteria:\n\n* History of hypersensitivity to any of the components of the drugs under investigation.\n* Use of ophthalmic medications from any pharmacological group.\n* Use of medications by any other route of administration.\n* Use of non-steroidal anti-inflammatory drugs, steroid anti-inflammatory drugs, or antibiotics by any route of administration in the last 30 days.\n* History of eye surgery in the last 6 months.\n* Use of contact lenses for a period less than two weeks prior to the start of the study, and during the intervention period of this study.\n* In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period.\n* Having participated in any clinical research study 30 days prior to inclusion in this study.\n* Having previously participated in this same study.\n* History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic Arterial Hypertension.\n* Diagnosis of glaucoma or ocular hypertension.\n* Known diagnosis of liver or heart disease.\n* Presenting active inflammatory or infectious disease at the time of entry into the study.\n* Presenting unresolved lesions or traumas at the time of entry into the study.\n* Having been subjected to non-ophthalmological surgical procedures in the last 3 months.\n* Being or having an immediate family member (e.g., spouse, parent\u002Flegal guardian, sibling, or child) who is an employee of the research site or the sponsor, and who directly participates in this study.\n* Active smoking (specified as the consumption of cigarettes regardless of the amount and frequency, 4 weeks prior to study inclusion and during the intervention period of this study).\n* Active alcoholism (specified as the consumption of alcoholic beverages, regardless of the amount and frequency, 72 hours prior to study inclusion and during the intervention period of this study).\n\nElimination Criteria:\n\n* Withdrawal of their consent to participate in the study (informed consent form).\n* Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and\u002For the sponsor, could affect the patient's fitness to safely continue with the study procedures.\n* Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine).\n* Non-tolerability or hypersensitivity to any of the drugs under investigation.\n* Adherence \\\u003C 80% determined by the subject's diary and corroborated by the final weight of the research products (RP) compared to the initial weight.",{"count":157,"type":20},[343],"PHASE1","This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®.",[26,346,347],"Dry Eye Sensation","Ocular Surface Disease","2025-03-18",{"date":350,"type":35},"2025-03-19",{"date":235,"type":20},{"date":353,"type":20},"2027-01-30",{"name":355,"class":42},"Laboratorios Sophia S.A de C.V.",{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":135},"100579079","characterization-of-subjective-discomfort-in-patients-with-tear-dysfunction-100579079","NCT06819631","Characterization of Subjective Discomfort in Patients With Tear Dysfunction","Retrospective and Observational Study in Relation to the Subjective Pain of Patients Attending the Corneal and Ocularcsurface Analysis Laboratory (LACSO) Affected by Ocular Surface Dysfunctions","Inclusion Criteria:\n\n* adult patients with suspected or diagnosed DED\n\nExclusion Criteria:\n\n* nothing",{"count":364,"type":20},12000,"Characterization of subjective discomfort\u002Fpain in patients with ocular surface dysfunction in association with clinical and laboratory parameters, for a better understanding of the underlying pathogenic mechanisms.",[26],"2025-02-10",{"date":369,"type":35},"2025-02-11",{"date":371,"type":20},"2025-03",{"date":373,"type":20},"2029-06-30",{"name":375,"class":134},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":383,"enrollmentInfo":384,"targetDuration":4,"studyType":21,"phases":386,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":135},"100569621","transcutaneous-auricular-vagus-nerve-stimulation-in-dry-eye-100569621","NCT06696625","Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye","Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye: a Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age \\>=18 and Age \\\u003C=65.\n2. complaint of DED symptoms for 6 months or longer at screening.\n3. ocular surface disease index (OSDI) score of 25 or higher.\n4. tear film breakup time (TFBUT) of 5 seconds or less.\n5. Schirmer I test without anesthesia of 5 mm or more at 5 minutes.\n6. tCFS score of 4 or higher.\n\nExclusion Criteria:\n\n1. History systemic autoimmune diseases and ocular\u002Fperiocular malignancy.\n2. Clinically relevant slitlamp findings or abnormal lid anatomy.\n3. Active ocular allergies and active infection.\n4. Pregnant or lactating women.","65 Years",{"count":385,"type":20},256,[23],"Objective: To evaluate the effect of transcutaneous auricular vagus nerve stimulation (taVNS) for the patients with dry eye disease.\n\nMethods: The investigators enrolled 256 patients at Beijing Tongren Hospital. Patients completed questionnaires at baseline, 1 month, 3 months, and 6 months. OSDI score, TBUT, Schirmer I, CFS, SF36, DEQ5, and psychological status to evaluate the therapeutic effects. A difference of P \\\u003C 0.05 was considered statistically significant.",[26],[390,391,392],"taVNS","Dry eye","RCT","2024-11-18",{"date":395,"type":35},"2024-11-20",{"date":397,"type":35},"2021-07-01",{"date":399,"type":20},"2025-12-01",{"name":401,"class":134},"Beijing Tongren Hospital",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":408,"enrollmentInfo":409,"targetDuration":4,"studyType":21,"phases":411,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":4},"100566532","effect-of-artificial-tears-on-ocular-biometry-parameters-100566532","NCT06656403","Effect of Artificial Tears on Ocular Biometry Parameters","Inclusion Criteria:\n\n(1) age ≥18 years,(2) able and willing to comply with the treatment schedule.\n\nExclusion Criteria:\n\n1. The eyes cannot fixate on the fixation lamp (such as children, nystagmus diseases, severe low vision, inattention, etc.) and cannot act according to the user's instructions and sit in the front of the equipment (the forehead or lower song is injured so that it cannot be supported on the forehead \u002F lower song bracket)\n2. The eyes are cloudy with optical media (such as corneal opacity, central corneal scar, mature cataract, posterior chamber bag opacity, vitreous hemorrhage, etc.).\n3. The eyelid is completely closed or too small (drooping, relaxation) resulting in complete or partial occlusion of the cornea\n4. Just after contact measurement or examination, use a corneal local anesthesia solution. (IOL Master 700 should avoid using local anesthetic before all contact examinations)\n5. Tear film deformation (lack of specular reflection of the cornea during corneal curvature measurement), the severity of grade IV dry eye, and whether eye drops were used 24 hours before the examination.\n6. Any corneal lesions (corneal irregularity, corneal scar or corrosive burning, severe irregular astigmatism of cornea)\n7. Fundus lesions (changes in the anatomical morphology of retinal macular fovea during axial length measurement, such as retinal detachment, edema, ulcer, etc.)\n8. Patients with ocular trauma, surgery, and excessive photosensitivity, such as photodynamic therapy (PDT), were excluded.\n9. using eye drops (0.1% Sodium hyaluronate) allergic patients","60 Years",{"count":410,"type":20},100,[23],"Due to the instability of the tear film, the biometry often needs to be done multiple times in a clinical environment. The high variability of both short-term and long-term repeatability in keratometry of dry eyes is well-known. Consequently, enhancing the condition of the eye surface in individuals with dry eyes will result in improved precision when choosing the power of intraocular lenses (IOLs). This prospective and before-and-after self-control study will recruit 100 patients.",[26,414],"Tear Film",[302,416,417],"IOL Master 700","tear film","2024-10-22",{"date":420,"type":35},"2024-10-24",{"date":422,"type":20},"2024-10-30",{"date":424,"type":20},"2024-11-21",{"name":426,"class":134},"He Eye Hospital",{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":383,"enrollmentInfo":434,"targetDuration":4,"studyType":21,"phases":436,"briefSummary":437,"conditions":438,"keywords":439,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":444,"leadSponsor":446,"locationsCount":111},"100414209","phase-2-transcutaneous-auricular-vagus-nerve-stimulation-in-dry-eye-disease-100414209","NCT04673643","Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye Disease","Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye Disease: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age \\>=18 and Age \\\u003C=75.\n2. Clinical diagnosis of dry eye disease.\n\nExclusion Criteria:\n\n1. History of depression, tumors, thyroid disease, diabetes, cardiac diseases.\n2. History of phthalmology surgery.\n3. Pregnant or lactating women.",{"count":435,"type":20},128,[146],"Objective: To evaluate the effect of transcutaneous auricular vagus nerve stimulation (taVNS) for the patients with dry eye disease with meibomian gland dysfunction.\n\nMethods: We enrolled 256 patients at Beijing Tongren Hospital. Patients completed questionnaires at baseline, 1 month, 3 months, and 6 months.OSDI score, TBUT, Schirmer I, tCFS, MGD score, and psychological status to evaluate the therapeutic effects. A difference of P \\\u003C 0.05 was considered statistically significant.",[26],[390,391,392],"2024-09-15",{"date":442,"type":35},"2024-09-19",{"date":397,"type":35},{"date":445,"type":20},"2024-10-20",{"name":401,"class":134},{"id":448,"slug":449,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":21,"phases":456,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":135},"100556504","phase-4-itear-single-center-open-label-single-arm-study-100556504","NCT06525961","iTear Single-center, Open-label, Single-arm Study","A Single-center, Open-label, Single-arm Study to Evaluate the Effectiveness and Safety of Extra Nasal Neurostimulator in Patients With Dry Eye Disease Dissatisfied With Artificial Tears","Inclusion Criteria:\n\nEach patient must meet all the following criteria to be enrolled in this study:\n\n1. Provided informed consent, approved by the Institutional Review Board (IRB), to participate in the study.\n2. Reported use of artificial tears for DED within 30 days of Visit 1.\n3. Ocular Surface Disease Index (OSDI) ≥ 23 (with no more than 3 N\u002FA in the answers).\n4. Anesthetized Schirmer Test Score ≤ 10 mm\u002F5 min in at least one eye.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will be excluded from the study:\n\n1. Used extranasal or intranasal neurostimulator within 30 days of Visit 1.\n2. Participation in any clinical trial with an investigational drug or device within 30 days of Visit 1.\n3. In the opinion of the investigator, any condition that could impair study participation\u002Focular evaluation or the potential risks of participation outweigh the potential benefits.",{"count":455,"type":20},30,[457],"PHASE4","This study aims to evaluate the effectiveness and safety of a device, iTEAR100 Neurostimulator (the device), which is designed to help people with Dry Eye Disease (DED) who are not satisfied with using artificial tears. The study will last three months and take place at one location. Thirty participants will use the iTEAR100 Neurostimulator, which stimulates the outside of the nose to help with dry eye symptoms.\n\nParticipants will have three main visits: one at the start (Day 0), one after 30 days (Day 30), and one at the end of the study (Day 90). For the first 30 days, they will use the device twice a day for 30 seconds on each side of the nose. After that, they will use it as needed for the next 60 days.\n\nBefore starting the treatment, participants will undergo tests to measure their initial eye condition. The effectiveness of the device will be checked by comparing these baseline measurements to those taken on Day 30 and Day 90. Participants will also fill out a questionnaire about their eye symptoms on Day 14.\n\nThe main measure of success is how much the participants' symptoms improve on the Ocular Surface Disease Index (OSDI) from Day 0 to Day 30. Other measures include changes in tear production, tear quality, and eye health from Day 0 to Days 30 and 90. Participants' safety will be monitored by tracking any adverse events (side effects) throughout the study.",[26,61,59,460],"Meibomian Gland Dysfunction",[59,213,61,462],"Meibomian Gland Dysfunction (MGD)","2024-07-23",{"date":465,"type":35},"2024-07-29",{"date":467,"type":20},"2024-08",{"date":469,"type":20},"2026-01",{"name":471,"class":134},"The University of Hong Kong",{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":16,"minAge":479,"maxAge":480,"enrollmentInfo":481,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":135},"100539057","the-pattern-of-dry-eye-disease-after-cataract-surgery-100539057","NCT06298890","The Pattern of Dry Eye Disease After Cataract Surgery","Ocular Surface and Corneal Morphological Changes After the Cataract Surgery and Associations With Inflammatory Biomarkers","Inclusion Criteria:\n\n* Cataract patients from 50 to 90 years old who underwent uncomplicated phacoemulsification performed by one (and same) experienced surgeon.\n* Patients with no underlying ocular surface diseases (keratitis, keratoconjunctivitis and others).\n* Patients who previously did not undergo any ophthalmic surgery.\n\nExclusion Criteria:\n\n* Patient expressed his wish to not participate in the study or discontinue it when already enrolled.\n* Severe dry eye disease diagnosed with OSDI\u002FDEQ-5 and at least one of the following tests: TBUT less than 10 seconds, tear osmolarity higher than 308 mOsm\u002Fl or positive corneal staining.\n* Glaucoma.\n* Diabetes mellitus.\n* Systemic connective tissue disease, autoimmune disease.\n* Neurologic conditions including stroke, Bell's palsy, Parkinson's, trigeminal nerve dysfunction.\n* Patients who underwent refractive surgery (LASIK or PRK).\n* Contact lens users.\n* One or more of the following concomitant medications: psychiatric medicines, antihistamines and\u002For hormonal replacement.\n* Patients who are already regularly using topical drops or ointments.","50 Years","90 Years",{"count":410,"type":20},"This study is designed to explore dry eye disease (DED) pattern: ocular surface, corneal morphological changes, patients' subjective assessment of DED and their correlations with ocular surface inflammation, pain biomarkers after cataract surgery according to ocular surface lubrication with artificial tears during long-term follow-up.",[26,484,347],"Cataract","2024-03-01",{"date":487,"type":35},"2024-03-07",{"date":489,"type":20},"2024-03",{"date":491,"type":20},"2027-09",{"name":493,"class":134},"Lithuanian University of Health Sciences"]